54 articles - From Friday Jan 20 2023 to Friday Jan 27 2023
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Nephrol Dial Transplant |
Management of heart failure in patients with kidney disease - updates from the 2021 ESC guidelines. Thirdly, guidelines for device therapy have been changed with down-graded advice on indications for primary prevention implantable cardioverter defibrillator therapy for patients with non-ischaemic heart failure and for cardiac resynchronisation therapy with left bundle branch block and a QRS duration < 150 ms. There are updated treatment plans for heart failure associated with non-cardiovascular co-morbidities including chronic kidney disease. |
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Am J Kidney Dis |
Anaphylaxis From Ethylene Oxide-Sterilized Dialysis Tubing and Needles: A Case Report. When use of the arteriovenous fistula was resumed, he was exposed to a higher "dose" of EtO due to use of needles. The higher antigenic stimuli triggered memory immune response leading to mast cell degranulation and repeated anaphylactic episodes that were overcome by minimization of EtO sterilized equipment, corticosteroid pretreatment and the anti-IgE Fc monoclonal, omalizumab. |
Predictors, Disparities, and Facility-Level Variation: SGLT2 Inhibitor Prescription Among US Veterans With CKD. Prescription for SGLT2i was low among likely eligible patients, with evident disparities by sex and race and between individual VA facilities. Efforts are needed to study and address the reasons for these disparities to improve equitable adoption of these important medications. |
Risks and Benefits of Different Dietary Patterns in CKD. Although each dietary pattern has its unique pros and cons, most healthful dietary patterns favor the inclusion of whole, unprocessed foods, preferably from plant-based sources. In this perspective, we discuss the risks and benefits of major popular diets to help guide health care professionals in treating patients with kidney disease. |
Stiripentol and Lumasiran as a Rescue Therapy for Oxalate Nephropathy Recurrence After Kidney Transplantation in an Adult Patient With Primary Hyperoxaluria Type 1. Fourteen months after transplantation, graft function, serum and urinary oxalate levels have remained stable, and kidney biopsy showed a complete regression of oxalate crystals. Further studies are needed to assess whether this strategy is effective and could replace liver-kidney transplantation. |
| Kidney Int |
A disease-modifying approach to the treatment of IgA nephropathy targeting mucosal IgA synthesis and beyond. Targeting the initiating pathogenetic event in the gut-associated lymphoid tissue would offer a disease-modifying approach to IgA nephropathy. Results, adverse events, and possible multiple effects of this treatment are critically discussed. |
Does kidney transplant improve health-related quality of life for youth with chronic kidney disease? In the current issue, Guha et al provide a longitudinal assessment of HRQOL for a cohort of youth with chronic kidney disease. Their findings suggest that children may experience meaningful improvement in HRQOL when they transition from dialysis to transplant. |
Down-regulation of G protein-coupled receptor kinase 4 protects against kidney ischemia-reperfusion injury. Kidney-targeted GRK4 silencing with nanoparticle delivery considerably ameliorated kidney ischemia/reperfusion injury. Thus, our findings reveal that GRK4 triggers necroptosis, aggravates kidney ischemia/reperfusion injury, and its down-regulation may provide a promising therapeutic strategy for kidney protection. |
Good and evil, more reasons to study UPR. Although accumulating evidence indicates the beneficial impact of the UPR pathway as a therapeutic target for various diseases, including kidney disease, the control of adaptive UPR status is still difficult for disease treatment. This article may give us a new insight into the strategy for sustaining the kidney protective UPR pathway. |
Osteopontin mediation of disturbed flow-induced endothelial mesenchymal transition through CD44 is a novel mechanism of neointimal hyperplasia in arteriovenous fistulae for hemodialysis access. In dysfunctional AVF of patients with uremia, expressions of osteopontin, CD44, and mesenchymal markers in endothelial cells overlying the neointima was also found by immunostaining. Thus, the osteopontin/CD44 axis regulates disturbed flow-induced EndMT, plays an important role in neointimal hyperplasia of AVF, and may act as a potential therapeutic target to prevent AVF dysfunction. |
TIPS to decide whether to prescribe aspirin for the primary prevention of cardiovascular events in chronic kidney disease. A post hoc subgroup analysis of the International Polycap Study 3 (TIPS-3) trial suggests that patients with chronic kidney disease might also benefit from aspirin for primary prevention. We consider the merits of doing so in practice. |
Toward a bona fide animal model of PLA2R1-associated membranous nephropathy: one step forward. Intriguingly, the transgenic mice spontaneously develop anti-human PLA2R1 antibodies and membranous nephropathy-like features, including immune deposits and nephrotic syndrome. The model raises questions about the spontaneous production of anti-human PLA2R1 antibodies and the additional steps to establish a bona fide animal model of membranous nephropathy. |
| Nephrol Dial Transplant |
Acute kidney injury in bortezomib-treated patients with multiple myeloma. Development of AKI was often observed in the absence of TLS in patients with MM after treatment with bortezomib. In addition, the risk factors of AKI and TLS varied widely. These findings indicate the potential nephrotoxicity of bortezomib irrespective of TLS in patients with decreased kidney function. |
Comparable outcomes between a combination of peritoneal dialysis with once-weekly hemodialysis and thrice-weekly hemodialysis: a prospective cohort study. PD+HD therapy was associated with similar or potentially lower mortality compared with thrice-weekly HD. Considering a flexible lifestyle, PD+HD therapy could be a great option. |
GFR estimated with creatinine rather than cystatin C is more reflective of the true risk of adverse outcomes with low GFR in kidney transplant recipients. eGFRcr better represents the true relationship between GFR and outcomes after kidney transplantation because it has less non-GFR residual association. Cystatin C is better interpreted as a non-specific prognostic biomarker than as eGFR in the kidney transplant setting. |
High rates of psychological distress, mental health diagnoses and suicide attempts in people with CKD in Ireland. People with CKD in Ireland experience high levels of psychological distress, mental health difficulties, suicidal ideation and suicide attempts. The identification of and intervention for mental health difficulties in CKD should be prioritised in clinical care. |
Iron deficiency and cognitive functioning in kidney transplant recipients: findings of the TransplantLines biobank and cohort study. Iron-deficient KTRs performed worse on neurocognitive tasks measuring memory, mental speed and attention and executive functioning. These findings set the stage for prospective studies addressing whether ID correction restores cognitive function after kidney transplantation. |
Long-term outcomes of COVID-19 survivors with hospital AKI: association with time to recovery from AKI. COVID-19 survivors who developed hospital AKI are at high risk for adverse cardiovascular and kidney outcomes, especially those with longer AKI recovery time and those with history of CKD. These patients may require long-term follow-up for cardiac and kidney complications. |
Pathological spectrum of hereditary transthyretin renal amyloidosis and clinicopathologic correlation: a French observational study. ATTRvN affects al kidney compartments, but compared to AL/AA amyloidosis, ATTRvN seems to involve more frequently tubulointerstitial areas. V30M patients represents the dominant face of the disease with a higher risk of glomerular/arteriolar involvement. ATTRvN should thus be considered in patients, and potential relatives, with ATTRv amyloidosis and kidney dysfunction, regardless of proteinuria level. |
The 3-Step Model of informed consent for living kidney donation: a proposal on behalf of the DESCaRTES Working Group of the European Renal Association. The 3-S Model successfully allows an integration between standardization and individualization of IC, enabling a person-centered approach to potential donors. Studies will assess the effectiveness of the 3-S Model in kidney transplant clinical practice. |
The impact of acute kidney injury with or without recovery on long-term kidney outcome in patients undergoing living liver transplantation. Post-LT AKI is associated with subsequent risk of CKD development. Taking into account recovery status, AKI was no longer associated with a higher risk of CKD if renal function recovered within 90 days after surgery. Identification and implementation of targeted and individualized therapies for patients at risk for AKI, particularly non-recovery AKI, is of paramount importance to reduce incident CKD in the follow up. |
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. FLOW will evaluate the effect of semaglutide on kidney outcomes in participants with CKD and T2D, and is expected to complete in late 2024. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Am J Kidney Dis |
| Kidney Int |
New advances in endocrine hypertension: from genes to biomarkers. In this review, we describe the physiology of adrenal hormone biosynthesis and action, the clinical and biochemical characteristics of different forms of endocrine HT, and their underlying genetic defects. We discuss the impact of these discoveries on diagnosis and management of patients, as well as new perspectives related to the use of new biomarkers for improved patient care. |
| Nat Rev Nephrol |
Exercise and chronic kidney disease: potential mechanisms underlying the physiological benefits. Exercise-mediated activation of the canonical wnt pathway may lead to bone formation and improvements in the levels of the bone-derived hormones klotho and fibroblast growth factor 23 (FGF23). Longer duration studies with larger sample sizes are needed to confirm these mechanisms in CKD, kidney failure and kidney transplant populations and provide evidence for targeted exercise interventions. |
Pathological consequences of DNA damage in the kidney. The emerging view is that in the kidney, DNA damage affects the local microenvironment by triggering a damage response and cell proliferation to replenish injured cells, as well as inducing systemic responses aimed at reducing exposure to genotoxic stress. The pathological consequences of DNA damage are therefore key to the nephrotoxicity of DNA-damaging agents and the kidney phenotypes observed in human DNA repair-deficiency disorders. |
The impact of intrauterine growth restriction and prematurity on nephron endowment. Furthermore, emerging research suggests that IUGR and/or preterm birth is associated with an elevated risk of chronic kidney disease in later life. The available data highlight the important role of early life development in the aetiology of kidney disease and emphasize the need to develop strategies to optimize nephron endowment in IUGR and preterm infants. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Kidney Dis |
| Kidney Int |
| Nat Rev Nephrol |
| Nephrol Dial Transplant |
Letters to the editors and authors’ replies
| Kidney Int |